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Abstract 
Background: Hemodynamically irrelevant pericardial effusion (PeEf) is a predictor of adverse 
outcome in heart failure patients. The clinical relevance of a PeEf unrelated to surgery in heart 
transplant patients remains unknown. This study assesses the prognostic value of PeEf occurring 
later than one year after transplantation.  
Methods: All patients undergoing heart transplantation in Zurich between 1989 and 2012 were 
screened. Cox proportional hazard models were used to analyse mortality (primary) and 
hospitalization (secondary endpoint). PeEf time points were compared to baseline for rejection, 
immunosuppressants, tumours, inflammation, heart failure, kidney function, hemodynamic, and 
echocardiographic parameters.  
Results: Of 152 patients (mean age 48.3 ± 11.9), 25 developed PeEf. Median follow-up period was 
11.9 (IQR 5.8–17) years. The number of deaths was 6 in the PeEf group and 46 in the non-PeEf 
group. The occurrence of PeEf was associated with a 2.5-fold increased risk of death (HR 2.49, 
95% CI 1.02–6.13, p = 0.046) and hospitalization (HR 2.53, 95% CI 1.57–4.1, p = 0.0002). 
Conclusions: This study reveals that the finding of hemodynamically irrelevant PeEf in heart 
transplant patients is a predictor of adverse outcome, suggesting that a careful clinical assessment is 
warranted in heart transplant patients exhibiting small PeEf. 
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INTRODUCTION 
Pericardial effusion (PeEf) is a common finding in the acute phase after heart transplantation. 
During the first months, moderate to severe PeEf has been described in up to 21% of patients and 
has been subject of several studies. In contrast, the development of PeEf later than 1 year after heart 
transplantation is rare and its clinical significance has not been investigated.  
Small and hemodynamically irrelevant PeEf, which may be observed during routine 
echocardiography, is associated with increased mortality in patients with chronic heart failure as 
well as in those with pulmonary hypertension. However, in patients after heart transplantation, the 
prognostic value of a hemodynamically irrelevant PeEf not related to surgery remains 
undetermined. Thus, the aim of this study was to assess the prognostic significance of this finding 
in patients one year or later after heart transplantation. 
 
METHODS 
Patient population and baseline characteristics 
All patients undergoing heart transplantation at the University Heart Center Zurich between 
August 1989 and July 2012 were retrospectively screened for inclusion in this study. Exclusion 
criteria were death within the first year after transplantation, age < 16 years at heart transplantation, 
and lack of echocardiography studies. Baseline was defined as the time of the first 
echocardiography study later than 1 year after heart transplantation. Data on age, gender, body 
weight, blood pressure, heart rate, primary heart disease (ischemic vs. non-ischemic), New York 
Heart Association (NYHA) functional class, International Society for Heart and Lung 
Transplantation (ISHLT) score, medication, and laboratory values were retrieved from local 
databases and patient records. Survival and hospitalization data was retrieved from the post-
transplant database and completed by detailed reviewing of electronic medical records as well as 
paper charts from the heart transplantation unit of the University Heart Center Zurich. The study 
was approved by the local ethical committee and complies with the Declaration of Helsinki. 
Informed consent was obtained from all subjects. 
 
Study groups and outcome measures 
Patients with no signs of PeEf were defined as the control group. Patients exhibiting a PeEf 
were assigned to the PeEf group at the first time point the PeEf was detected and remained in this 
group until the end of the study. Hence, with each occurrence of a PeEf, the composition of the two 
groups changes, as a patient moves from the control to the PeEf group. The primary outcome 
measure was all-cause mortality. The secondary outcome measure was unscheduled hospitalization 
for any cause. 
 
Echocardiography 
All echocardiograms available were included in the analysis and were analysed independently 
by two experienced physicians. In general, echocardiograms were performed when applicable every 
2 years, additionally  whenever clinically indicated. The presence of a hemodynamically irrelevant 
PeEf was defined as an end-diastolic hypoechogenic space in the pericardium without signs of 
hemodynamic compromise (inversion or collapsing of right side heart chambers, abnormal 
ventricular septal motion, respiratory variation of mitral inflow > 25%). Other echocardiographic 
parameters were analysed according to guidelines of the European Society of Cardiology including 
grading of mitral and tricuspid regurgitation, tricuspid annular plane systolic excursion (TAPSE), 
mitral annular plane systolic excursion, left ventricular end-diastolic volume and ejection fraction, 
end-diastolic diameter, end-systolic diameter, left ventricular mass index, left atrial end-systolic 
diameter, right ventricular (RV) end-diastolic diameter, right atrial dimensions (RA long and short 
axis), fractional area change, and systolic RV-RA pressure gradient (∆p RV-RA). 
 
Laboratory and histological parameters 
Blood samples were taken during clinical routine follow-up (usually every 6 months in the 
heart failure and heart transplantation clinic) as well as during unscheduled hospitalization. C-
reactive protein (CRP) and creatinine levels were analysed using the Cobas analyser (Roche 
Diagnostics, Basel, Switzerland) at the Institute of Clinical Chemistry of the University Hospital 
Zurich. 
Right ventricular septal endomyocardial biopsies were performed according to the post-
transplant surveillance program of the documented heart transplantation clinic and cardiac cellular 
allograft rejection grading was performed according to the International Society for Heart and Lung 
Transplantation (ISHLT guidelines). In general, endomyocardial biopsies were performed when 
applicable every 6 months, additionally when otherwise indicated. 
 
Statistical analysis 
Statistical analysis was performed by the Epidemiology, Biostatistics and Prevention Institute 
in the Department of Biostatistics at the University of Zurich. The time-dependent variable PeEf 
was taken into account as described in Anderson et al. 1983 (“Mantel-Byar Approach”) and 
Andersen 1992, and modelled with a Cox regression with age as time scale and with or without 
adjustment for age at transplantation and gender. Transition from non-PeEf- to PeEf group was 
taken into account by creating a data set listing the time-dependent group variable for each follow-
up visit of  patients and the time span during which the assignment to a group did not change. In 
this model, all patients belong to the group without PeEf at the beginning of the observation and 
shift to the other group, as soon as they develop PeEf. Thus, groups are not constant and direct 
statistical comparison of the groups with the final distribution was not performed. Statistical 
analysis of not normally distributed parameters at baseline vs. time of PeEf was performed using the 
Wilcoxon signed-rank test. A p-value < 0.05 was considered statistically significant. As statistical 
software, the R programming language Version 3.4.1 was applied.  
 
RESULTS 
Patient population and echocardiography findings 
All 313 patients undergoing heart transplantation at the University Heart Center Zurich 
between August 1989 and July 2012 were evaluated for this study. Exclusion criteria were death 
within the first year after transplantation (64 patients), age < 16 years at heart transplantation (8 
patients), and lack of echocardiography studies (89 patients, mostly due to follow up in other 
hospitals). A total of 152 patients were included in the study (supplemental Figure). Clinical 
baseline characteristics of the study population are displayed in Table 1. Most of the patients were 
male (84.9%) and had transplants due to non-ischemic heart disease (65%). Mean age at 
transplantation was 48.3 ± 11.9 years. Median follow-up duration was 11.9 (IQR 5.8–17) years. 
Baseline echocardiography was performed after a median of 3 (IQR 1.5–9.5) years post heart 
transplantation. Echocardiographic baseline characteristics are displayed in Table 1. Moderate or 
severe tricuspid regurgitation was frequent (n = 22, 15.2%). Twenty-five patients developed PeEf 
over time with a PeEf incidence of 14.4 per 1000 patient-years. First diagnosis of PeEf occurred 
after a median of 11.1 (IQR 4.1–14) years after heart transplantation. Hemodynamically relevant 
PeEf did not occur in any patients. Except for one, all PeEf were small with a maximal width of 1 
cm in diastole. The one large (but also hemodynamically irrelevant) PeEf exhibited spontaneous 
regression without recurrence. At the time of occurrence, broad examinations revealed that it was 
most likely triggered by a viral polyserositis. 
Direct comparison of patient groups was not legitimate since patients exhibiting a PeEf were 
assigned to the PeEf group at the first time point whenPeEf was detected and remained in this group 
until the end of the study. Hence, with each occurrence of PeEf, the composition of the two groups 
changed (as described in the methods section). 
 
Mortality 
The total number of deaths was 6 in patients with PeEf and 46 in those without PeEf. When 
adjusted for age at transplantation and gender, the occurrence of PeEf was associated with a 2.5-
fold increase in the risk of death (adjusted hazard ratio 2.49, 95% CI 1.02–6.13, p = 0.046). In the 
unadjusted analysis, there was a trend towards increased mortality (unadjusted hazard ratio 2.27, 
95% CI 0.95–5.47, p = 0.066). The probability of survival for patients with PeEf as compared to 
patients never developing PeEf is depicted in Figure 1A (for demonstration purposes, the time-point 
of first PeEf is hypothetically set to baseline). 
Causes of death are depicted in Figure 1B. Cancer was the main reason for death (n = 15, 
28.8%), followed by infection (n = 8, 15.4%), heart failure (n = 7, 13.4%), and cardiac allograft 
vasculopathy (n = 4, 7.7%). In 2 (3.8%) patients, rejection, bleeding, or renal failure was the cause 
of death, respectively. Other causes of death included 2 perioperative complications, 1 documented 
arrhythmia, 1 pulseless electrical activity, and 1 stroke. In 7 patients, death occurred for unknown 
reasons. 
 
Hospitalization 
The absolute number of unscheduled hospitalizations was 42 in patients with PeEf and 136 in 
patients without PeEf. Median interval between transplantation and the first unscheduled 
hospitalization was 5.6 (IQR 3–10) years. Median duration of hospitalization was 8 (IQR 6-15) 
days. In a Cox proportional hazard model, the risk of being admitted for hospitalization was 
significantly increased in patients exhibiting a prior PeEf compared to patients without PeEf 
(unadjusted hazard ratio 2.53, 95% CI 1.57–4.1, p = 0.0002). Figure 2A compares the probability of 
freedom from unscheduled hospitalization in patients with PeEf with patients never developing 
PeEf (for demonstration purposes, the time-point of first PeEf is hypothetically set to baseline).  
The main reason for hospitalization (Fig. 2B) was infection (n = 137, 47.6%), followed by a 
heterogeneous group of predominantly arterial and venous cardiovascular problems (n = 30, 10.4%) 
and cancer (n = 20, 6.9%). No hospitalizations were because of pericardial effusion. 
 
Characterization of patients at the time of pericardial effusion 
To evaluate possible causes of PeEf, patients developing PeEf were characterized in more 
detail. Paired analysis for comparison of various parameters at the time of PeEf versus baseline 
revealed no difference for most parameters (Table 2). In particular, rejection stage, inflammation 
parameters, renal function, left ventricular function, right ventricular dimensions and tricuspid 
regurgitation were comparable at both time points. 
NYHA functional class exhibited a trend towards higher stages at the time of PeEf as 
compared to baseline (median 1 IQR 1–1.875 vs. 2 IQR 1.125–2, p = 0.053, n = 14), whereas the N-
terminal fragment of prohormone B-type natriuretic peptide (NT-proBNP) did not differ 
significantly. Left atrial size as assessed by LA-ESD was larger at the time of PeEf (median 4.05 
IQR 3.75–5.1 vs. 5.2 IQR 4.38–5.55 cm, p = 0.021, n = 12). Systolic blood pressure was reduced at 
the time of PeEf (median 136.5 IQR 130–142 vs. 117.5 IQR 111.2–128 mm Hg; p = 0.004, n = 14). 
Longitudinal shortening of the right ventricle as assessed by TAPSE was also decreased under these 
conditions (median 18 IQR 18–22 vs. 17 IQR 15–19 mm, p = 0.033, n = 7). 
The temporal relationship between the detection of PeEf and the time of transplantation was 
also evaluated. There was a linear increase in the number of patients affected by a PeEf with time 
after transplantation. No association pattern was detectable regarding the incidence of PeEf and the 
time after transplantation (Fig. 3A). Similarly, the incidence of malignant tumours was examined in 
relation to the time-point of PeEf. No association was evident between the incidence of malignant 
tumours and that of PeEf (Fig. 3B). Immunosuppressant medication was comparable at baseline and 
time of PeEf (Table 3). Sirolimus was prescribed in 3 patients at the time of PeEf whereas it was not 
prescribed at baseline. 
 
DISCUSSION 
This study reveals that the presence of a hemodynamically irrelevant PeEf occurring unrelated 
to surgery in heart transplant patients is a predictor of mortality and unscheduled hospitalization. 
PeEf occurring during the first year after heart transplantation were not included in this analysis 
since PeEf in this period is usually related to surgery, resolves spontaneously usually within three 
months, and is associated with recipient-donor weight mismatch and possibly rejection. 
In this study, the incidence of PeEf was 14.4 per 1000 patient-years during follow-up. No 
association of PeEf with the time after transplantation was observed. This is in contrast to another 
study demonstrating a continuous decrease in the incidence of PeEf after transplantation . In that 
study, however, the first year after transplantation was included and the average follow-up was no 
more than 3 years, suggesting that many surgery-related PeEf were considered. This type of PeEf is 
a common finding and associated with transplantation-independent surgical risk. In the present 
population, however, about half of the PeEf not related to surgery occurred more than 10 years after 
transplantation. 
It was observed that patients with PeEf were at a 2.5-fold higher risk of death than those 
remaining free of PeEf. This is in line with studies assessing the prognostic value of PeEf in 
patients with heart failure or pulmonary hypertension . In patients with or without PeEf, the main 
causes of death were cancer and infections, followed by heart failure and cardiac allograft 
vasculopathy. This is consistent with the latest report of The Registry of the International Society 
for Heart and Lung Transplantation reporting malignant tumours, rejection-independent graft 
failure, infection, cardiac allograft vasculopathy, and failure of other organs as the main reasons for 
long-term mortality in heart transplant recipients . These findings suggest that the PeEf observed in 
the present population might not be associated with a specific pathologic condition but rather be a 
general prognostic indicator for a worse clinical course. 
To further characterize the prognostic value of small PeEf, hospitalization rates were studied. 
The hazard of being hospitalized was 2.5-fold higher in patients diagnosed with PeEf at any time 
compared to patients without PeEf. The steep decrease (Fig. 2A) in the probability for remaining 
free of hospitalization in the PeEf group early during observation is mainly driven by a single 
patient who had a PeEf documented on day 485 and was subsequently hospitalized three times in 
rapid succession due to causes not related to PeEf. Exclusion of this patient, however, did not alter 
the results significantly (hazard ratio 2.24, 95% CI 1.33–3.77). Infection was the reason for almost 
half of hospitalizations, followed by cardiovascular complications, cancer, and rejection. Similar to 
these findings, infections have been reported to be the leading cause for hospitalization during the 
first 5 years after transplantation. 
To evaluate possible causes for the development of PeEf, patients with PeEf were analysed in 
detail. At the time-point of PeEf no difference was observed when compared to baseline for most 
parameters such as rejection stage, inflammation parameters, renal function, left ventricular 
function, right ventricular size, and tricuspid regurgitation. NYHA functional class and left atrial 
size, however, were elevated, whereas NT-proBNP remained unchanged. This discrepancy may be 
due to the fact that the NYHA classification evaluates the occurrence of symptoms which are often, 
but not exclusively, due to heart failure. Several studies showed that different comorbidities like 
depression, anaemia, chronic obstructive pulmonary disease, and others can significantly reduce 
NYHA functional class. Thus, alterations in NYHA functional class can be multifactorial and are 
partially driven by a patient’s general condition. The increase in left atrial size may represent 
elevated filling pressures, even though it is not solely dependent on diastolic pressure, particularly 
in transplanted hearts. Interestingly, systolic blood pressure was reduced at the time of PeEf. It is 
well known, that a reduced systolic blood pressure is associated with negative prognosis in multiple 
clinical settings, such as heart failure, infection, pulmonary embolism, and myocardial infarction. In 
light of this, the differences in NYHA class and blood pressure are most likely multifactorial and 
may be considered a marker for increased morbidity in general. The reduction in TAPSE was also 
significant. However, in contrast to the other parameters quantitative change and patients having 
measured TAPSE at both time points was low, so that it seems clinically negligible. As expected in 
transplanted patients, relevant tricuspid regurgitation was more frequent in patients having a PeEf at 
a later stage (> 12 years after transplantation), suggesting that in these situations tricuspid 
dysfunction may be more relevant in contributing to PeEf than in patients at earlier stages. 
Hypothesizing that PeEf could be related to malignancy, analysis of the temporal context of 
PeEf and the time of diagnosis of malignant tumours was also performed. However, no association 
pattern was evident, suggesting that even though cancer was the leading cause of death in this 
population, most PeEf were not of malignant origin. Similarly, CRP was comparable at both time 
points (baseline and PeEf), even though infection was the second most common cause of death. 
Hence, neither tumours nor infections seem to induce a PeEf in a direct manner, again pointing to 
the interpretation that the occurrence of a small PeEf in a transplant recipient is a general marker of 
increased mortality and morbidity. 
Immunosuppressant medication was comparable during baseline and at the time of PeEf with 
the exception of sirolimus. The latter was described to be associated with PeEf in a small study (4 
PeEf in 25 patients). In the present population, it was part of the medication in 3 patients with PeEf 
whereas it was not prescribed at baseline. Hence, sirolimus may at least in part account for the PeEf 
in these 3 patients. 
Taking all these data into account, this study suggests that the aetiology of PeEf is variable 
and may often be multifactorial (heart failure, malignancy, infection, and others), suggesting that 
the finding of PeEf in a heart transplant patient should lead to further investigation for excluding 
potentially treatable pathologies not necessarily related to cardiac function per se. 
Given the observational, retrospective study design, the limitation of this study is a possible 
confounding bias (taking into account that echocardiograms were performed during regular follow-
up as well as for clinical reasons) additionaly the problem of informative but missing measurements 
of patients not requiring medical care or those being examined in other hospitals.  
 
CONCLUSIONS 
In summary, this study reveals that the echocardiographic finding of a hemodynamically 
irrelevant PeEf in heart transplant patients is a predictor of adverse outcome, evidenced by a 2.5 
times higher risk of both death and hospitalization. Thus, a small PeEf — which may be observed 
during routine echocardiography — should be regarded as a “red flag”, leading to further 
examination of the patient with a focus on potentially treatable causes not directly related to the 
PeEf. 
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Table 1. Baseline characteristics of all patients. 
 
 
Baseline n 
Clinical parameters   
Age [years] 48.3 ± 11.9 152 
Male 129 (84.9%) 152 
BMI [kg/m2] 26.3 ± 5.1 145 
Systolic BP [mm Hg] 136.5 ± 15.4 28 
Heart rate [bpm] 85.7 ± 13.1 139 
   
Ischemic heart disease 53 (34.9%) 152 
Non-ischemic heart disease 99 (65.1%) 152 
   
Echocardiography   
LVEF [%] 60.9 ± 7.4 122 
LV EDV [mL] 89.7 ± 23.4 98 
LV EDD [mm] 47 ± 5.1 135 
LV ESD [mm] 29 ± 5.5 134 
LVMMI [g/m2] 98.4 ± 27.7 102 
LA ESD [mm] 48 ± 10 136 
MAPSE [mm] 15.6 ± 2.8 60 
   
Mitral regurgitation: ≥ moderate 1 (0.7%) 143 
Tricuspid regurgitation: moderate 13 (9.0%) 145 
Tricuspid regurgitation: severe 9 (6.2%) 145 
   
FAC [%] 43.2 ± 9.3 51 
TAPSE [mm] 18.4 ± 4.3 66 
RVEDD [mm] 32 ± 6.5 94 
RA long axis [mm] 53 ± 9 124 
RA short axis [mm] 39 ± 7.5 119 
   
∆p RV-RA [mm Hg] 27.1 ± 8.1 117 
Values presented as mean mean ± standard deviation or number and percentage;  BMI — body 
mass index; BP — blood pressure; EDD — end-diastolic diameter; EDV — end-diastolic volume; 
ESD — end-systolic diameter; FAC — fractional area change; LA — left atrium; LV — left 
ventricle; LVEF — left ventricular ejection fraction; LVMMI — left ventricular mass index; 
MAPSE — mitral annular plane systolic excursion; RA — right atrium; RV — right ventricle; 
TAPSE — tricuspid annular plane systolic excursion; ∆p — pressure gradient 
 
 
Table 2. Analysis of parameters at baseline vs. time of pericardial effusion (PeEf) in patients 
developing a PeEf and having the parameters assessed at both time points.  
 Baseline Time of PeEf P 
Rejection     
ISHLT stage  1.0 (0.0–1.0) 1.0 (0.0–1.0) NS 
    
Inflammation and kidney function    
CRP [mg/L] 3.0 (1.50–10.55) 19.0 (3.05–67.00) NS 
Leucocytes [G/L] 6.75 (4.94–8.16) 6.34 (5.02–8.15) NS 
Creatinine [μmol/] 156 (142–179) 131 (104–219)  NS 
    
Heart failure     
NYHA class [1–4] 1.00 (1.00–1.875) 2.00 (1.125–2.00) 0.053 
Body weight [kg] 79.0 (68.3–89.8) 76.0 (67.0–89.0) NS 
NT-proBNP [ng/L] 465 (146–1577) 534 (166–2555) NS 
    
Blood pressure and heart rate     
Systolic BP [mm Hg] 136.5 (130.0–142.0) 117.5 (111.2–128.0) 0.004 
Heart rate [bpm] 91 (80–98) 88 (79–91) NS 
    
Echocardiography    
LVEF [%] 62.5 (60.0–64.0) 61.5 (59.0–64.8) NS 
LAESD [cm] 4.05 (3.75–5.10) 5.20 (4.38–5.55) 0.021 
Mitral regurgitation (1–4) 1.0 (1.0–1.0) 1.0 (1.0–2.0) NS 
Tricuspid regurgitation (1–4) 1.0 (1.0–2.0) 2.0 (1.0–2.0) NS 
∆p RV-RA [mm Hg] 25.0 (20.0–28.5) 28.0 (22.0–29.0) NS 
TAPSE [mm] 18 (18–22) 17 (15–19) 0.033 
Values are presented as median (1st–3rd quartile). BP — blood pressure; CRP — C-reactive protein; 
ESD — end-systolic diameter; ISHLT — International Society for Heart and Lung Transplantation; 
LA — left atrium; LAESD — left atrial end-systolic diameter; LVEF — left ventricular ejection 
fraction; NT-proBNP — N-terminal fragment of prohormone brain natriuretic peptide; NYHA — 
New York Heart Association; RA — right atrium; RV — right ventricle; TAPSE — tricuspid 
annular plane systolic excursion; ∆p — pressure gradient. 
 
 
Table 3. Specific immunosuppressant therapy at baseline versus at time of pericardial effusion 
(PeEf) (all patients who developed a PeEf). 
Medication Baseline Time of PE 
Ciclosporin 12 (71%) 15 (60%) 
Azathioprine 11 (65%) 13 (52%) 
Cortisone 9 (53%) 12 (48%) 
Mycophenolic acid 6 (35%) 10 (40%) 
Tacrolimus 5 (29%) 6 (24%) 
Everolimus 2 (12%) 1 (4%) 
Sirolimus 0 (0%) 3 (12%) 
 
 
Figure 1. A. Separate estimated survivor functions for patients after heart transplantation. The solid 
black line is the survivor function for patients without pericardial effusion (PeEf); the broken line is 
for patients who showed at least once a PeEf (for demonstration purposes, the time-point of first 
PeEf is hypothetically set to baseline); B. Cause of death in all patients (52 deaths). 
 
 
Figure 2A: Separate estimated functions depicting freedom from unscheduled admission to a 
hospital for patients after heart transplantation. The solid black line is the function for patients 
without pericardial effusion (PeEf); the broken grey line is for patients who showed at least once a 
PeEf (for demonstration purposes, the time-point of first PeEf is hypothetically set to baseline);  
B. Cause of hospitalization in all patients (137 hospitalizations). 
 
 
Figure 3. A. Diagnosis of pericardial effusion (PeEf) (blue lines) and its temporal relation to heart 
transplantation (dotted line) in all patients with PeEf; 25 patients, 30 PeEf; B. Diagnosis of 
malignant tumours (red lines) and its temporal relation to first PeEf (dotted line) in all patients with 
PeEf and tumour diagnosis; 15 patients, 30 tumours. 



